搜索
Tenax Therapeutics Inc
TENX添加自选
13.700USD
-1.400-9.27%
收盘 07-31 16:00（美东）报价延迟15分钟
512.71M总市值
亏损市盈率 TTM
关于 Tenax Therapeutics Inc 公司
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Tenax Therapeutics Inc简介
公司代码TENX
公司名称Tenax Therapeutics Inc
上市日期Oct 28, 1993
CEOGiordano (Christopher T)
员工数量4
证券类型Ordinary Share
年结日Oct 28
公司地址101 Glen Lennox Drive
城市CHAPEL HILL
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编27517
电话19198552100
网址http://www.tenaxthera.com/
公司代码TENX
上市日期Oct 28, 1993
CEOGiordano (Christopher T)
Tenax Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
常见问题
Tenax Therapeutics Inc的前五大股东是谁？
Tenax Therapeutics Inc 的前五大股东如下：Dr. Stuart Rich, M.D.
有多少机构持有Tenax Therapeutics Inc(TENX)的股份？
截至2026Q1，共有74家机构持有Tenax Therapeutics Inc的股份，合计持有的股份价值约为11.71M，占公司总股份的51.15%。与2025Q4相比，机构持股有所增加，增幅为5305648.00。